LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 3, 2005, Pages 1134-1143

  Kristof, Arnold S ^a,b   Pacheco Rodriguez, Gustavo ^a   Schremmer, Bruno ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2 PIPERAZINYL 8 PHENYL 4H 1 BENZOPYRAN 4 ONE; ANTINEOPLASTIC AGENT; BENZOPYRAN DERIVATIVE; CASEIN KINASE II; CYCLINE; LY 303511; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTERY MUSCLE; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CASEIN KINASE II; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; HUMANS; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PIPERAZINES; PROSTATIC NEOPLASMS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY ARTERY; RIBOSOMAL PROTEIN S6 KINASES;

EID: 23944439701     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083550     Document Type: Article

References (40)

1. Ahmed K, Gerber DA, and Cochet C (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12:226-230.
2. Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, and Schreiber SL (1993) FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem 268:22825-22829.
3. Altmann C, Steenpass V, Czyborra P, Hein P, and Michel MC (2003) Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine. Br J Pharmacol 138:261-271.
4. Ammit AJ and Panettieri RA Jr (2001) Invited review: the circle of life: cell cycle regulation in airway smooth muscle. J Appl Physiol 91:1431-1437.
5. Bjornsti MA and Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348.
6. Blume-Jensen P and Hunter T (2001) Oncogenic kinase signalling. Nature (Lond) 411:355-365.
7. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, and Schreiber SL (1995) Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature (Lond) 377:441-446.
8. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, and Abraham RT (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO (Eur Mol Biol Organ) J 15:5256-5267.
9. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, and McCubrey JA (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590-603.
10. Chen X, Lowe M, and Keyomarsi K (1999) UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 18:5691-5702.
11. Choi EK, Park HJ, Ma JS, Lee HC, Kang HC, Kim BG, and Kang IC (2004) LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism. FEBS Lett 559:141-144.
12. Chou MM, Masuda-Robens JM, and Gupta ML (2003) Cdc42 promotes G1 progression through p70 S6 kinase-mediated induction of cyclin E expression. J Biol Chem 278:35241-35247.
13. Dancey J and Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296-313.
14. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
15. De AW Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, and Kim SH (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93:2735-2740.
16. Ding J, Vlahos CJ, Liu R, Brown RF, and Badwey JA (1995) Antagonists of phosphatidylinositol 3-kinase block activation of several novel protein kinases in neutrophils. J Biol Chem 270:11684-11691.
17. Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB, and Seldin DC (2000) Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J Biol Chem 275:22245-22254.
18. Fruman DA and Cantley LC (2002) Phosphoinositide 3-kinase in immunological systems. Semin Immunol 14:7-18.
19. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, and Lichtenstein AK (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279:2737-2746.
20. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, and Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62:6141.
21. Hidayat S, Yoshino K, Tokunaga C, Hara K, Matsuo M, and Yonezawa K (2003) Inhibition of amino acid-mTOR signaling by a leucine derivative induces G1 arrest in Jurkat cells. Biochem Biophys Res Commun 301:417-423.
22. Hu L, Zaloudek C, Mills GB, Gray J, and Jaffe RB (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6:880-886.
23. Huang S, Bjornsti MA, and Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2:222-232.
24. Knudsen ES and Wang JY (1996) Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271:8313-8320.
25. Kristof AS, Marks-Konczalik J, Billings E, and Moss J (2003) Stimulation of STAT1-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. J Biol Chem 278:33637-33644.
26. Kristof AS, Marks-Konczalik J, and Moss J (2001) Mitogen-activated protein kinases mediate AP-1-dependent human inducible nitric oxide synthase promoter activation. J Biol Chem 276:8445-8452.
27. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS, Lee KS, and Lee YC (2003) Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Investig 111:1083-1092.
28. Landesman-Bollag E, Channavajhala PL, Cardiff RD, and Seldin DC (1998) p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 16:2965-2974.
29. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369:1-15.
30. Luo J, Manning BD, and Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:257-262.
31. Marks AR (2003) Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 349:1307-1309.
32. Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, and Albrecht JH (2003) Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem 278:3656-3663.
33. Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, and Gutkind JS (1998) Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Investig 102:1674-1681.
34. Pepperkok R, Lorenz P, Ansorge W, and Pyerin W (1994) Casein kinase II is required for transition of G0/G1, early G1 and G1/S phases of the cell cycle. J Biol Chem 269:6986-6991.
35. Peterson RT, Beal PA, Comb MJ, and Schreiber SL (2000) FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 275:7416-7423.
36. Raught B, Gingras AC, and Sonenberg N (2001) The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 98:7037-7044.
37. Reddy MA, Prasadarao NV, Wass CA, and Kim KS (2000) Phosphatidylinositol 3-kinase activation and interaction with focal adhesion kinase in Escherichia coli K1 invasion of human brain microvascular endothelial cells. J Biol Chem 275:36769-36774.
38. Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27-36.
39. Vermeulen K, Van Bockstaele DR, and Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131-149.
40. Vlahos CJ, Matter WF, Hui KY, and Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.